
ASCO GU 2022
CONTENTS
Online First
Prostate Cancer
First-line treatment with olaparib significantly improves PFS in mCRPC

First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC
Darolutamide improves OS in mHSPC
Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide

Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence
PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel

Artificial intelligence improves prediction of long-term outcomes
Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer
Addition of abiraterone to ADT/docetaxel does not increase bone loss
Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity
Urothelial Carcinoma
No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma
Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma

Positive efficacy and safety of N-803 plus BCG infusion in BCG-unresponsive NMIBC
Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma
Maintenance niraparib fails to improve PFS in advanced urothelial cancer
First-line avelumab shows clinical activity in advanced urothelial carcinoma
Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma

Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma
Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer
Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin
Renal Cell Carcinoma
High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib
